V
Valeria Biggio
Researcher at French Institute of Health and Medical Research
Publications - 10
Citations - 1026
Valeria Biggio is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Leukemia & CEBPA. The author has an hindex of 8, co-authored 10 publications receiving 973 citations. Previous affiliations of Valeria Biggio include university of lille.
Papers
More filters
Journal ArticleDOI
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Aline Renneville,Christophe Roumier,Valeria Biggio,Olivier Nibourel,N Boissel,Pierre Fenaux,Claude Preudhomme +6 more
TL;DR: This nonexhaustive review aims to show how gene mutations interact with each other, how they contribute to refine prognosis and how they can be useful for risk-adapted therapeutic management of AML patients.
Journal ArticleDOI
Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.
Nicolas Boissel,Aline Renneville,Valeria Biggio,Nathalie Philippe,Xavier Thomas,Jean-Michel Cayuela,Christine Terré,Isabelle Tigaud,Sylvie Castaigne,Emmanuel Raffoux,Stéphane de Botton,Pierre Fenaux,Hervé Dombret,Claude Preudhomme +13 more
TL;DR: NPM mutations were detected in 47% of patients and were associated with a high white blood cell count, involvement of the monocytic lineage (M4/M5), and a decreased prevalence of CEBPA mutations.
Journal ArticleDOI
CEBPA point mutations in hematological malignancies.
Hugues Leroy,Christophe Roumier,Pauline Huyghe,Valeria Biggio,Pierre Fenaux,Claude Preudhomme +5 more
TL;DR: Systematic analysis of CEBPA mutations, in addition to that of alterations in master genes of hematopoiesis, may be useful to assess the prognosis of AML particularly in patients belonging to the ‘intermediate’ prognostic subgroup of MRC classification.
Journal ArticleDOI
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-γ
Selim Corm,Céline Berthon,Michel Imbenotte,Valeria Biggio,Michel Lhermitte,Caroline Dupont,Isabelle Briche,Bruno Quesnel,Bruno Quesnel,Bruno Quesnel +9 more
TL;DR: In patients with acute myeloid leukemia (AML), the serum kynurenine/tryptophan ratio (Kyn/Trp) was raised, suggesting a higher IDO activity than in healthy people, providing a tool for future clinical testing of IDO-blocking drugs.
Journal ArticleDOI
Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association.
Aline Renneville,Aline Renneville,Nicolas Boissel,Virginie Zurawski,Virginie Zurawski,Laura Llopis,Laura Llopis,Valeria Biggio,Valeria Biggio,Olivier Nibourel,Olivier Nibourel,Nathalie Philippe,Nathalie Philippe,Xavier Thomas,Hervé Dombret,Claude Preudhomme,Claude Preudhomme +16 more
TL;DR: WT1 mutations occur in approximately 10% of normal karyotype AMLs and are an independent predictor of poor outcome in this subgroup of patients with AML.